Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649077 | Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg | PHASE1 | COMPLETED | 30 | — | — | Aug 1, 2004 | Sep 1, 2004 | Apr 24, 2024 | 1 | United States |
| NCT00649675 | Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg | PHASE1 | COMPLETED | 27 | — | — | Aug 1, 2004 | Sep 1, 2004 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Meloxicam Tablets 15 mg |
| 2 | ACTIVE_COMPARATOR | Mobic® Tablets 15 mg |
| Name | Type | Description |
|---|---|---|
| Meloxicam Tablets 15 mg | DRUG | 15mg, single dose fasting |
| Mobic® Tablets 15 mg | DRUG | 15mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administrati...